Medtech

Migraine treatment company receives million-dollar infusion from EU

With DKK 19m from an EU program, the medical technology company Rehaler is able to quadrable the number of ongoing clinical trials. 
With the EU-granted capital infusion, medtech company Rehaler is able to expand its ongoing clinical trial of the company's migraine device. | Photo: Rehaler / Pr
With the EU-granted capital infusion, medtech company Rehaler is able to expand its ongoing clinical trial of the company's migraine device. | Photo: Rehaler / Pr
by albert rønning-andersson, translated by katrine gøthler

Denmark-based medtech company Rehaler has received a capital infusion and grant of DKK 11m, and another DKK 8m in equity investment by the EU’s EIC accelerator program, thus totaling a sum of DKK 19m (USD 2.78).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Related articles

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs